ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.

Publication/Presentation Date

9-21-2021

Abstract

The BCL2-inhibitor, Venetoclax (VEN), has shown significant anti-leukemic efficacy in combination with the DNMT-inhibitor, Azacytidine (AZA). To explore the mechanisms underlying the selective sensitivity of mutant leukemia cells to VEN and AZA, we used cell-based isogenic models containing a common leukemia-associated mutation in the epigenetic regulator ASXL1. KBM5 cells with CRISPR/Cas9-mediated correction of the ASXL1

Volume

11

Issue

9

First Page

157

Last Page

157

ISSN

2044-5385

Disciplines

Medicine and Health Sciences

PubMedID

34548471

Department(s)

Department of Medicine

Document Type

Article

Share

COinS